Natera Inc (NTRA)
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-09-09
$330.31+1.90%
Close 2026-09-09 · 1-day change
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-09-09
Warn: Management is running behind on a stated commitment.
Natera is growing revenue fast, with guidance raised to about $2.78 billion in 2026. Its gross margin is improving, guided at 64%-66%. The company won a key legal case and gained regulatory approval in Japan, expanding its market. Strategic partnerships support future growth.
Natera remains unprofitable with negative EPS expected through 2026. The company faces risks from high R&D costs and recent earnings misses. Its valuation is rich relative to current profits, and growth may slow if execution falters.
The market prices in about 21% revenue growth and values Natera roughly 18% above our fair value of $237. Our fair value is below the Street median, reflecting caution on profitability and execution risks.
Breaks if: Gross margin falls below 62% in FY26
Maintain and improve gross margin in the 64% to 66% range through cost reductions and pricing.
Stated as a priority in 3 of last 3 quarters. Gross margin was 64.7% in 2026-Q1 and 64.5% in 2026-Q2, consistent with guidance of 64% to 66%. Non-GAAP gross margin improved sequentially by 0.5% in 2026-Q2. The trajectory shows stable margin performance aligned with management's stated target.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity in the healthcare sector. The current thesis state is weakened, with recent financial performance dropping significantly.
The market appears to have priced in a justified valuation, with a low expectations gap. NTRA is trading at a premium compared to peers, suggesting some optimism is already reflected in its valuation.
Management has shown stable execution in increasing revenue guidance, but gross margin and R&D cost management are mixed. The near-term risk of missing earnings is low, but the company has a history of erratic earnings surprises.
Key factors for the future include management's ability to maintain or improve guidance, sector performance from leading companies, and the impact of economic conditions on healthcare stocks. Any cuts in guidance or worsening economic indicators could negatively affect NTRA.
The most important moves since the prior daily snapshot.
Yes, our read has weakened. NTRA's recent financial performance fell to the 37th percentile. This is a drop from the robust 57th percentile of its sector. The company raised its full-year revenue guidance after beating Q2 estimates. However, the reason to own it has weakened.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“2026 gross margin to be approximately 64% to 66%; non-GAAP gross margin increased 0.5% sequentially.”
“Gross margin increased to 64%-66%.”
“Gross margin of 63% to 65% established for 2026.”
Breaks if: Loss of key legal cases or regulatory approvals
Breaks if: R&D costs exceed $850 million in FY26
Breaks if: Annual revenue falls below $2.74 billion in FY26
Continue to grow revenue with raised 2026 guidance reflecting strong test volume and pricing improvements.
Stated as a priority in 2 of last 2 quarters. Revenue grew from $696.6 million in 2026-Q1 to $752.8 million in 2026-Q2 (+8.1%). Management raised 2026 annual revenue guidance midpoint by $100 million from $2.78 billion to $2.88 billion. The trajectory is delivering with consistent revenue growth and upward guidance revisions.
“Raised 2026 annual revenue guidance by $100 million at the midpoint, from $2.74 billion - $2.82 billion to $2.85 billion - $2.91 billion.”
“Raising 2026 annual revenue guidance by $120 million at the midpoint, from $2.62 billion - $2.70 billion to $2.74 billion - $2.82 billion.”
In the next 1 to 3 years, NTRA's performance will depend on management's execution and external market conditions. Not investment advice.